JPRN-UMIN000037200
Completed
未知
A study to investigate the efficacy and dose response of Euglena by questionnaires for a measure of the subjective well-being - A study to investigate the efficacy and dose response of Euglena by questionnaires for a measure of the subjective well-being
everage Brain Inc.0 sites210 target enrollmentJuly 3, 2019
ConditionsHealthy individuals
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Healthy individuals
- Sponsor
- everage Brain Inc.
- Enrollment
- 210
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Subjects who are under pharmacological treatment for chronic disorders, especially subjects who take Warfarin 2\)Subjects who have histories of mental disorders (Depression etc.) 3\)Subjects work irregular hours on the night shift or irregular shift 4\)Subjects who had participated in other clinical trials or monitoring studies within 1 month 5\)Subjects who have intolerance to study food substance 6\)Subjects who are in pregnancy, lactation, or who are willing to become pregnant 7\)Subjects who are ineligible due to the chief inspector's judgment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Dose Response Study of a Complementary Medicine Formulation in Primary HypercholesterolaemiaACTRN12605000232639Pathways40
Completed
Not Applicable
A study to evaluate the dose-response efficacy of body fat reduction by continuous ingestion of test food. (SWE-2023-07-HCRINK)ot applicableJPRN-UMIN000051748Suntory Wellness Limited200
Active, not recruiting
Not Applicable
Dose finding study (phase II) to investigate efficacy and tolerability of a 6 month oral treatment with three different strenghts of selenium (trade name: Cefasel) compared to placebo in patients with autoimmune thyroiditis (Hashimoto's disease, inflammation of the thyroid):double blind, random allocation to treatment groupsEUCTR2007-001107-38-DECefak KG200
Active, not recruiting
Not Applicable
Study to investigate how efficient and how safe are tablets of house dust mite allergens for patients with house dust mite allergic asthmahouse dust mite-associated allergic asthmaMedDRA version: 17.0Level: LLTClassification code 10020419Term: House dust mite allergySystem Organ Class: 100000004870MedDRA version: 17.0Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 100000004855Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2013-000487-28-DESTALLERGENES SA480
Active, not recruiting
Phase 1
Study to investigate how efficient and how safe are tablets of house dust mite allergens for patients with house dust mite allergic asthmahouse dust mite-associated allergic asthmaMedDRA version: 14.1Level: LLTClassification code 10020419Term: House dust mite allergySystem Organ Class: 100000004870MedDRA version: 14.1Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 100000004855Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2013-000487-28-SKSTALLERGENES SA480